Does BTKi improve CAR T-cell therapy in MCL? Editorial
| Authors: | Boardman, A. P.; Palomba, M. L. |
| Title: | Does BTKi improve CAR T-cell therapy in MCL? |
| Keywords: | adult; treatment failure; clinical feature; review; flow cytometry; neurotoxicity; outcome assessment; cd8+ t lymphocyte; t lymphocyte; t-lymphocytes; interleukin 2; mantle cell lymphoma; editorial; antineoplastic activity; minimal residual disease; piperidines; adoptive immunotherapy; cell expansion; immunotherapy, adoptive; immunocompetent cell; lymphoma, mantle-cell; adenine; memory t lymphocyte; piperidine derivative; clinical outcome; ibrutinib; humans; human; tisagenlecleucel t; antineoplastic monoclonal antibody; chimeric antigen receptor t-cell immunotherapy; bruton tyrosine kinase inhibitor; lisocabtagene maraleucel; brexucabtagene autoleucel; unmet medical need |
| Journal Title: | Blood |
| Volume: | 143 |
| Issue: | 8 |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-02-22 |
| Start Page: | 653 |
| End Page: | 655 |
| Language: | English |
| DOI: | 10.1182/blood.2023022898 |
| PUBMED: | 38386430 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Editorial -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
